20
Participants
Start Date
June 15, 2020
Primary Completion Date
December 1, 2022
Study Completion Date
May 1, 2023
Ustekinumab
All patients will receive intravenously (IV) ustekinumab \~6mg/kg at baseline and subcutaneously (SC) ustekinumab 90mg every 8 weeks thereafter until Week 48.
Cliniques Universitaires Saint-Luc, Brussels
UZ Leuven, Leuven
CHU de Liège, Sart Tilman, Liège
Collaborators (1)
Janssen Pharmaceuticals
INDUSTRY
Universitaire Ziekenhuizen KU Leuven
OTHER